J Gastroenterol Hepatol:HCV血清阳性与糖尿病相关

2012-12-13 J Gastroenterol Hepa J Gastroenterol Hepa

 ?     据报道,丙型肝炎病毒(HCV)感染与2型糖尿病(T2DM)相关。我们的研究旨在阐明,在HCV流行地区甘油三酯(TG) 和胆固醇(CHOL)水平在抗-HCV阳性和2型糖尿病的联系中所起的作用。        研究人员分析了56,338位居民的数据,该数据来自台湾台南县一个以社区为基础的全面筛查项目。空腹血糖

       据报道,丙型肝炎病毒(HCV)感染与2型糖尿病(T2DM)相关。我们的研究旨在阐明,在HCV流行地区甘油三酯(TG) 和胆固醇(CHOL)水平在抗-HCV阳性和2型糖尿病的联系中所起的作用。

       研究人员分析了56,338位居民的数据,该数据来自台湾台南县一个以社区为基础的全面筛查项目。空腹血糖,抗-HCV状态,乙型肝炎表面抗原(HBsAg)状态,血小板计数,甘油三酯水平,胆固醇水平,年龄,性别,身体质量指数被列入分析中。多元回归分析被用来确定糖尿病的独立相关因素。

       结果发现, 年龄,肥胖,高胆固醇血症,高甘油三酯血症,血小板减少症,抗-HCV阳性和乙肝病毒表面抗原抗体阴性,是糖尿病常见的独立相关因素。在所有多重逻辑回归分析,用于确定2型糖尿病的独立相关因素的模型中,丙型肝炎病毒血清阳性只在包括高甘油三酯血症或高胆固醇血症的模型中被确定。当受试者分为高血脂组(胆固醇>200,或甘油三酯>150mg/dL;n=33,393)和非高血脂分组(胆固醇<200,甘油三酯<150mg/dL;n=22,945),抗-HCV阳性只有在非高血脂亚组被确定作为一个独立的因素。比值比为1.35,95%CI 1.17-1.55。

       这项研究表明,HCV血清阳性个体有较高的2型糖尿病和非高脂血症的患病率。如果不考虑血脂水平,HCV血清阳性和2型糖尿病之间的联系并不存在。进一步的病理生理的研究是必要的。




Background and Aims
Hepatitis C virus (HCV) infection is reported to be associated with or to cause type 2 diabetes mellitus (T2DM). Our study aimed to elucidate the role of triglyceride (TG) and cholesterol (CHOL) levels in the association between anti-HCV seropositivity and T2DM in an HCV-endemic area.
Methods
We analyzed a computerized dataset of 56 338 residents from a community-based comprehensive screening program in Tainan County in southern Taiwan. Fasting glucose, anti-HCV status, hepatitis B surface antigen (HBsAg) status, platelet counts, TG levels, CHOL levels, age, gender, and body mass index were included in the analyses. Multivariate logistic analysis was used to identify factors independently associated with T2DM.
Results
Older age, being overweight, thrombocytopenia, hypertriglyceridemia, hypercholesterolemia, anti-HCV seropositivity, and HBsAg seronegativity were common factors independently associated with diabetes. Among all models of multiple logistic regression analysis used for identifying factors independently associated with T2DM, anti-HCV seropositivity was only identified in the models that included either hypertriglyceridemia or hypercholesterolemia. When subjects were divided into hyperlipidemia (CHOL, > 200 or TG, > 150 mg/dL; n = 33 393) or non-hyperlipidemia subgroups (CHOL, < 200 and TG, < 150 mg/dL; n = 22 945), anti-HCV seropositivity was identified as an independent factor only in the non-hyperlipidemia subgroup. The odds ratio was 1.35, with a 95% confidence interval of 1.17–1.55.
Conclusions
This study demonstrates that the lipid level is associated with the relationship between T2DM and anti-HCV seropositivity in non-hyperlipidemic individuals. However, the relationship between HCV and T2DM did not exist when the lipid level was not included in the analysis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2071462, encodeId=8e7d20e146297, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu May 09 07:00:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710616, encodeId=3a731e1061677, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063821, encodeId=004c2063821ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Tue Mar 12 06:00:00 CST 2013, time=2013-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257557, encodeId=1a17125e557e6, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426516, encodeId=13f21426516ec, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537812, encodeId=5958153e8128a, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=)]
    2013-05-09 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2071462, encodeId=8e7d20e146297, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu May 09 07:00:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710616, encodeId=3a731e1061677, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063821, encodeId=004c2063821ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Tue Mar 12 06:00:00 CST 2013, time=2013-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257557, encodeId=1a17125e557e6, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426516, encodeId=13f21426516ec, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537812, encodeId=5958153e8128a, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2071462, encodeId=8e7d20e146297, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu May 09 07:00:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710616, encodeId=3a731e1061677, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063821, encodeId=004c2063821ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Tue Mar 12 06:00:00 CST 2013, time=2013-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257557, encodeId=1a17125e557e6, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426516, encodeId=13f21426516ec, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537812, encodeId=5958153e8128a, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2071462, encodeId=8e7d20e146297, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu May 09 07:00:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710616, encodeId=3a731e1061677, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063821, encodeId=004c2063821ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Tue Mar 12 06:00:00 CST 2013, time=2013-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257557, encodeId=1a17125e557e6, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426516, encodeId=13f21426516ec, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537812, encodeId=5958153e8128a, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=)]
    2012-12-14 ymljack
  5. [GetPortalCommentsPageByObjectIdResponse(id=2071462, encodeId=8e7d20e146297, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu May 09 07:00:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710616, encodeId=3a731e1061677, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063821, encodeId=004c2063821ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Tue Mar 12 06:00:00 CST 2013, time=2013-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257557, encodeId=1a17125e557e6, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426516, encodeId=13f21426516ec, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537812, encodeId=5958153e8128a, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=)]
    2012-12-14 gwc384
  6. [GetPortalCommentsPageByObjectIdResponse(id=2071462, encodeId=8e7d20e146297, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu May 09 07:00:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710616, encodeId=3a731e1061677, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063821, encodeId=004c2063821ef, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Tue Mar 12 06:00:00 CST 2013, time=2013-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257557, encodeId=1a17125e557e6, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426516, encodeId=13f21426516ec, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537812, encodeId=5958153e8128a, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Dec 14 15:00:00 CST 2012, time=2012-12-14, status=1, ipAttribution=)]

相关资讯

中国-印度尼西亚肝病峰会会议纪要

       印度尼西亚大学医学院和雅加达Cipto Mangunkusumo博士教学医院Laurentius Lesmana教授指出:CHB患者中,血清高HBsAg和肝内高共价闭合环状(ccc) DNA含量与晚期肝纤维化有关。对于处于免疫清除期的患者,高水平的血清HBsAg和肝内cccDNA反应了肝病在进展。CHB患在接受核苷(酸)类似

Gut:摄入维生素B12有助于治疗丙型肝炎

       根据Gut期刊上最新发表的的一项研究显示,加入维生素B12到标准丙型肝炎病毒(hepatitis C virus, HCV)治疗之中能够显著性地增强机体抵抗这种病毒感染的能力。这项研究还表明该效果在感染HCV之后很难被有效治疗的病人身上特别强烈。       十年前

替拉瑞韦对部分基因Ⅰ型HCV患者更有益

       自2011年秋季之后替拉瑞韦(商品名Incivo?)已被用于基因型1慢性丙型肝炎的治疗。根据“药用产品市场改革法” (AMNOG) 进行的一项早期获益评估中, 德国药物评估局(IQWiG)调查了替拉瑞韦与目前的标准治疗相比,是否还可提供额外的益处。       根据

JAMA:乳蓟提取物治疗慢性丙型肝炎没有裨益

芝加哥–据7月18日刊《美国医学会杂志》JAMA上的一项研究披露,使用植物产品水飞蓟素——一种某些病人常常用来治疗慢性肝脏疾病的乳蓟提取物——对那些对治疗有抵抗性的慢性丙型肝炎病毒(HCV)感染的患者而言其裨益并不比安慰剂更多。 慢性丙型肝炎病毒感染影响了全球人口中的近3%,它可能会导致肝硬化、肝功能衰竭及肝癌。有很大比例的患者对这种感染的某些治疗不做出反应,有许多其他的患者则因为并存的疾病而无

J HEPATOL:博赛泼维药物组合治晚期纤维化/肝硬化安全有效

       源自丙型肝炎病毒(HCV)基因1型的晚期纤维化/肝硬化的患者,对聚乙二醇干扰素-利巴韦林联合博赛泼维(Boceprevir)有时会有持续的病毒学应答(SVR),早期结果可以反映应答,研究人员报道。        布鲁诺博士在电子邮件写道:“大多数肝硬化患者(METAVIR评分分级 F4),HCV